Affordable Access

deepdyve-link
Publisher Website

Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis.

Authors
  • Hirai, Fumihito1, 2
  • Takeda, Teruyuki3, 4
  • Takada, Yasumichi4
  • Kishi, Masahiro3, 4
  • Beppu, Tsuyoshi3, 4
  • Takatsu, Noritaka3
  • Miyaoka, Masaki4
  • Hisabe, Takashi4
  • Yao, Kenshi4
  • Ueki, Tosiharu4
  • 1 Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan. [email protected] , (Japan)
  • 2 Department of Gastroenterology, Fukuoka University Faculty of Medicine, 7-45-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. [email protected] , (Japan)
  • 3 Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan. , (Japan)
  • 4 Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan. , (Japan)
Type
Published Article
Journal
Journal of gastroenterology
Publication Date
Oct 22, 2019
Identifiers
DOI: 10.1007/s00535-019-01634-1
PMID: 31641874
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Enteral nutrition (EN) is effective in Crohn's disease (CD) patients and has been shown to have an inhibitory effect on loss of response to anti-tumor necrosis factor (TNF)-alpha antibody therapy; however, the current level of evidence is not sufficient. The objective of this meta-analysis was to determine whether EN in combination anti-TNF-alpha antibody therapy is useful in maintaining remission. PubMed was used to identify all relevant studies. A total of nine articles were identified including one randomized control trial, two prospective cohort studies, and six retrospective cohort studies. We performed a meta-analysis on all these articles to assess the remission maintenance effect of EN (n = 857). The remission or response maintenance effect in the EN group was 203/288 (70.5%), which was higher than 306/569 (53.8%) in the non-EN group. The odds ratio for long-term remission or response using fixed effects model and random effects model were 2.23 (95% CI 1.60-3.10) and 2.19 (95% CI 1.49-3.22), respectively. The usefulness of EN was unclear in two prospective studies that were conducted immediately after remission induction with anti-TNF-alpha antibody therapy was detected. Differences in the definition of relapse and the observation period among articles were considered to be limitations. This analysis suggests that EN is effective for maintaining remission in patients already in remission or response as a result of anti-TNF-alpha antibody maintenance therapy.

Report this publication

Statistics

Seen <100 times